255 related articles for article (PubMed ID: 34302010)
1. Clinical utility of a serum biomarker panel in distinguishing prostate cancer from benign prostate hyperplasia.
Kiebish MA; Tekumalla P; Ravipaty S; Dobi A; Srivastava S; Wu W; Patil S; Friss T; Klotz A; Srinivasan A; Cullen J; Rosner IL; Ali A; Laszlo S; Petrovic M; Fleshner N; Garren J; Miller G; Mahaveer Chand N; Rodrigues LO; Granger E; Kellogg MD; Luan S; Diamandis E; Akmaev VR; Sarangarajan R; Bountra C; Freedland SJ; McLeod DG; Narain NR
Sci Rep; 2021 Jul; 11(1):15052. PubMed ID: 34302010
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic and prognostic value of serum miR-15a and miR-16-1 expression among egyptian patients with prostate cancer.
Zidan HE; Abdul-Maksoud RS; Elsayed WSH; Desoky EAM
IUBMB Life; 2018 May; 70(5):437-444. PubMed ID: 29522280
[TBL] [Abstract][Full Text] [Related]
3. [Improved discrimination between prostatic carcinoma and benign prostatic hyperplasia by determination of free prostate-specific antigen percentage].
Wolff JM; Borchers H; Boeckmann W; Habib FK; Jakse G
Urologe A; 1997 May; 36(3):255-8. PubMed ID: 9265347
[TBL] [Abstract][Full Text] [Related]
4. Differential blood-based diagnosis between benign prostatic hyperplasia and prostate cancer: miRNA as source for biomarkers independent of PSA level, Gleason score, or TNM status.
Leidinger P; Hart M; Backes C; Rheinheimer S; Keck B; Wullich B; Keller A; Meese E
Tumour Biol; 2016 Aug; 37(8):10177-85. PubMed ID: 26831660
[TBL] [Abstract][Full Text] [Related]
5. Urinary Polyamines: A Pilot Study on Their Roles as Prostate Cancer Detection Biomarkers.
Tsoi TH; Chan CF; Chan WL; Chiu KF; Wong WT; Ng CF; Wong KL
PLoS One; 2016; 11(9):e0162217. PubMed ID: 27598335
[TBL] [Abstract][Full Text] [Related]
6. Filamin A Is a Prognostic Serum Biomarker for Differentiating Benign Prostatic Hyperplasia from Prostate Cancer in Caucasian and African American Men.
Mahaveer Chand N; Tekumalla PK; Rosenberg MT; Dobi A; Ali A; Miller GM; Aristizabal-Henao JJ; Granger E; Freedland SJ; Kellogg MD; Srivastava S; McLeod DG; Narain NR; Kiebish MA
Cancers (Basel); 2024 Feb; 16(4):. PubMed ID: 38398103
[TBL] [Abstract][Full Text] [Related]
7. Additional value of the ratio of serum total testosterone to total prostate-specific antigen in the diagnosis of prostate cancer in a Chinese population.
Xu L; Hu X; Zhu Y; Lu J; Xu Y; Wang G; Guo J
Andrologia; 2018 Mar; 50(2):. PubMed ID: 28752596
[TBL] [Abstract][Full Text] [Related]
8. Investigation on core-fucosylated prostate-specific antigen as a refined biomarker for differentiation of benign prostate hyperplasia and prostate cancer of different aggressiveness.
Lang R; Rolny V; Leinenbach A; Karl J; Swiatek-de Lange M; Kobold U; Schrader M; Krause H; Mueller M; Vogeser M
Tumour Biol; 2019 Mar; 41(3):1010428319827223. PubMed ID: 30907281
[TBL] [Abstract][Full Text] [Related]
9. Prostate Specific Antigen, Mean Platelet Volume, and Platelet Distribution Width in Combination to Discriminate Prostate Cancer from Benign Prostate Hyperplasia.
Fu S; Zhang X; Niu Y; Wang RT
Asian Pac J Cancer Prev; 2018 Mar; 19(3):699-702. PubMed ID: 29580043
[TBL] [Abstract][Full Text] [Related]
10. Plasma Sarcosine Measured by Gas Chromatography-Mass Spectrometry Distinguishes Prostatic Intraepithelial Neoplasia and Prostate Cancer from Benign Prostate Hyperplasia.
Markin PA; Brito A; Moskaleva N; Fodor M; Lartsova EV; Shpot YV; Lerner YV; Mikhajlov VY; Potoldykova NV; Enikeev DV; Lyundup AV; Appolonova SA
Lab Med; 2020 Nov; 51(6):566-573. PubMed ID: 32161964
[TBL] [Abstract][Full Text] [Related]
11. IGF-II serum levels increase discrimination between benign prostatic hyperplasia and prostate cancer and improve the predictive value of PSA in clinical staging.
Trojan L; Bode C; Weiss C; Mayer D; Grobholz R; Alken P; Michel MS
Eur Urol; 2006 Feb; 49(2):286-92; discussion 292. PubMed ID: 16386354
[TBL] [Abstract][Full Text] [Related]
12. Frequency of Unnecessarily Biopsies among Patients with Suspicion of Prostate Cancer in Syrian Men.
Bachour DM; Chahin E; Al-Fahoum S
Asian Pac J Cancer Prev; 2015; 16(14):5967-70. PubMed ID: 26320481
[TBL] [Abstract][Full Text] [Related]
13. [Prognostic significance of prostate-specific antigen in defining indications for initial prostate biopsy].
Popov SV; Guseinov RG; Skryabin ON; Orlov IN; Martov AG
Urologiia; 2018 Jul; (3):92-97. PubMed ID: 30035426
[TBL] [Abstract][Full Text] [Related]
14. Serum proteomic profiling can discriminate prostate cancer from benign prostates in men with total prostate specific antigen levels between 2.5 and 15.0 ng/ml.
Ornstein DK; Rayford W; Fusaro VA; Conrads TP; Ross SJ; Hitt BA; Wiggins WW; Veenstra TD; Liotta LA; Petricoin EF
J Urol; 2004 Oct; 172(4 Pt 1):1302-5. PubMed ID: 15371828
[TBL] [Abstract][Full Text] [Related]
15. MMP26: A potential biomarker for prostate cancer.
Cheng T; Li F; Wei R; Lv MQ; Zhou Y; Dai Y; Yuan Y; Jiang GY; Ma D; Gao QL
J Huazhong Univ Sci Technolog Med Sci; 2017 Dec; 37(6):891-894. PubMed ID: 29270749
[TBL] [Abstract][Full Text] [Related]
16. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.
Kachakova D; Mitkova A; Popov E; Popov I; Vlahova A; Dikov T; Christova S; Mitev V; Slavov C; Kaneva R
DNA Cell Biol; 2015 Mar; 34(3):189-200. PubMed ID: 25521481
[TBL] [Abstract][Full Text] [Related]
17. Autoantibody signatures as biomarkers to distinguish prostate cancer from benign prostatic hyperplasia in patients with increased serum prostate specific antigen.
O'Rourke DJ; DiJohnson DA; Caiazzo RJ; Nelson JC; Ure D; O'Leary MP; Richie JP; Liu BC
Clin Chim Acta; 2012 Mar; 413(5-6):561-7. PubMed ID: 22146597
[TBL] [Abstract][Full Text] [Related]
18. Correlation of serum β2-microglobulin levels with prostate-specific antigen, Gleason score, clinical stage, tumor metastasis and therapy efficacy in prostate cancer.
Zhang YX; Wang L; Ji PY; Zhao GG; Zhong GP; Wang ZP
Arch Med Res; 2013 May; 44(4):259-65. PubMed ID: 23707648
[TBL] [Abstract][Full Text] [Related]
19. Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer?
Jung K; Elgeti U; Lein M; Brux B; Sinha P; Rudolph B; Hauptmann S; Schnorr D; Loening SA
Clin Chem; 2000 Jan; 46(1):55-62. PubMed ID: 10620572
[TBL] [Abstract][Full Text] [Related]
20. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
Haese A; Graefen M; Steuber T; Becker C; Noldus J; Erbersdobler A; Huland E; Huland H; Lilja H
J Urol; 2003 Dec; 170(6 Pt 1):2269-73. PubMed ID: 14634394
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
